Melanoma and Immunotherapy

被引:41
作者
Eggermont, Alexander M. M. [1 ]
Schadendorf, Dirk [2 ]
机构
[1] Erasmus Univ, Dept Surg Oncol, MC Daniel den Hoed Canc Ctr, NL-3075 EA Rotterdam, Netherlands
[2] Univ Hosp Essen, Dept Dermatol, D-45122 Essen, Germany
关键词
Melanoma; Immunotherapy; Cytokines; Antibodies; Vaccines; Review; RANDOMIZED PHASE-III; METASTATIC MALIGNANT-MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; TUMOR-INFILTRATING LYMPHOCYTES; HIGH-DOSE INTERLEUKIN-2; HIGH-RISK MELANOMA; STAGE-IV MELANOMA; CD8(+) T-CELLS; AMERICAN JOINT COMMITTEE; NODE-NEGATIVE MELANOMA;
D O I
10.1016/j.hoc.2009.03.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.
引用
收藏
页码:547 / +
页数:20
相关论文
共 118 条
[41]   Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells [J].
Gattinoni, L ;
Finkelstein, SE ;
Klebanoff, CA ;
Antony, PA ;
Palmer, DC ;
Spiess, PJ ;
Hwang, LN ;
Yu, ZY ;
Wrzesinski, C ;
Heimann, DM ;
Surh, CD ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) :907-912
[42]   Adoptive immunotherapy for cancer: building on success [J].
Gattinoni, L ;
Powell, DJ ;
Rosenberg, SA ;
Restifo, NP .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :383-393
[43]   Prognostic significance of autoimmunity during treatment of melanoma with interferon [J].
Gogas, H ;
Ioannovich, J ;
Dafni, U ;
Stavropoulou-Giokas, C ;
Frangia, K ;
Tsoutsos, D ;
Panagiotou, P ;
Polyzos, A ;
Papadopoulos, O ;
Stratigos, A ;
Markopoulos, C ;
Bafaloukos, D ;
Pectasides, D ;
Fountzilas, G ;
Kirkwood, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07) :709-718
[44]  
GOMEZNAVARRO J, 2007, J CLIN ONCOL, V26
[45]   Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies [J].
Gray, Juliet C. ;
French, Ruth R. ;
James, Sonya ;
Al-Shamkhani, Aymen ;
Johnson, Peter W. ;
Glennie, Martin J. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (09) :2499-2511
[46]   Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1•5 mm without clinically detectable node metastases [J].
Grob, JJ ;
Dreno, B ;
de la Salmonière, P ;
Delaunay, M ;
Cupissol, D ;
Guillot, B ;
Souteyrand, P ;
Sassolas, B ;
Cesarini, JP ;
Lionnet, S ;
Lok, C ;
Chastang, C ;
Bonerandi, JJ .
LANCET, 1998, 351 (9120) :1905-1910
[47]  
Hamid O., 2008, J CLIN ONCOL, V26
[48]   Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma:: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG) [J].
Hauschild, A ;
Garbe, C ;
Stolz, W ;
Ellwanger, U ;
Seiter, S ;
Dummer, R ;
Ugurel, S ;
Sebastian, G ;
Nashan, D ;
Linse, R ;
Achtelik, W ;
Mohr, P ;
Kaufmann, R ;
Fey, M ;
Ulrich, J ;
Tilgen, W .
BRITISH JOURNAL OF CANCER, 2001, 84 (08) :1036-1042
[49]   Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy [J].
Heinzerling, L ;
Burg, G ;
Dummer, R ;
Maier, T ;
Oberholzer, PA ;
Schultz, J ;
Elzaouk, L ;
Pavlovic, J ;
Moelling, K .
HUMAN GENE THERAPY, 2005, 16 (01) :35-48
[50]   Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial [J].
Hersey, P ;
Coates, AS ;
McCarthy, WH ;
Thompson, JF ;
Sillar, RW ;
McLeod, R ;
Gill, PG ;
Coventry, BJ ;
McMullen, A ;
Dillon, H ;
Simes, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4181-4190